Phase 3 N=102 Periodontal Infection and Endothelial Dysfunction
Periodontitis
Primary: Brachial Artery Flow-mediated Dilation — 10.2; 10.3; 13.1; 8.1 Percentage of dilatation of brachial art — p=0.98
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,059 A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Change in Serum Phosphorus Levels From Week 24 to Week 27 — 0.25; 1.92 mg/dL
Phase 3 N=513 Clinical Trial Ceftriaxone in Subjects With ALS
Amyotrophic Lateral Sclerosis · ALS
Primary: Survival — 664; 581 days
Phase 3 N=838 Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
Influenza · Influenza Vaccines
Primary: Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain. — 175; 184; 201; 0 Subject
Phase 3 N=639 Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
Major Depressive Disorder
Primary: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the…
Phase 3 N=579 Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
Neoplasms, Breast
Primary: Time to Progression as Evaluated by the Investigator — 29.0; 22.9 weeks — p=0.142
Phase 3 N=10 A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects
Obesity
Primary: AUC Post Surgery (n =5) Compared to AUC Control (n=5) — 124.4; 314.8 ng-hr/mL
Phase 3 N=74 Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
Acute Myeloid Leukemia
Primary: Percentage of Patients With Overall Complete Response for Stage I — 35.4; 11.5 percentage of participants
Phase 3 N=329 A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
Actinic Keratosis
Primary: Complete Clearance of AKs at Week 11 — 101; 80 participants
Phase 3 N=61 Craving, Binge Eating and Obesity
Binge Eating Disorder · Obesity
Primary: Frequency of Binge Eating Episodes — 0.8; 1.0 episodes/week
Phase 3 N=1,183 PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Metastatic Colorectal Cancer
Primary: Progression-free Survival — 9.6; 8.0; 7.3; 8.8 months — p=0.0234
Phase 3 N=23 Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management
Sleep Apnea, Obstructive · Diabetes Mellitus, Type 2
Primary: Physical Activity, Steps Walked — 5892; 6071; 6284; 6684 steps walked
Phase 3 N=357 A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
Post-Operative Pain
Primary: Patient Global Satisfaction — 78.5; 65.6 % patients reporting good or excellent — p=<0.001
Phase 3 N=484 Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
Infection, Human Immunodeficiency Virus
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 — 90; 83 Percentage of…
Phase 3 N=275 Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 52; 56.5 estimated percentage of participants